Advice
following an abbreviated submission
dutasteride plus tamsulosin (Combodart®) is accepted for use within NHS Scotland.
Indication under review: Treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH); Reduction in the risk of acute urinary retention and surgery in patients with moderate to severe symptoms of BPH.
Download detailed advice42KB (PDF)
Medicine details
- Medicine name:
- dutasteride plus tamsulosin (Combodart)
- SMC ID:
- 628/10
- Indication:
- Treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH); Reduction in the risk of acute urinary retention and surgery in patients with moderate to severe symptoms of BPH.
- Pharmaceutical company
- GlaxoSmithKline UK Ltd
- BNF chapter
- Obstetrics, gynaecology, and urinary-tract disorders
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 09 August 2010